Unum Therapeutics
ne Broadway 4th Floor
Cambridge
Massachussetts
02142
United States
Tel: 1-617-843-5032
Website: http://www.unumrx.com/
28 articles about Unum Therapeutics
-
Unum Therapeutics announced on Monday that it has successfully completed its acquisition of Kiq LLC, a privately held biotechnology company with a focus on the discovery and development of precision kinase inhibitors.
-
Clinical Catch-Up: March 9-13
3/16/2020
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look. -
The company disclosed that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I trial for non-Hodgkin lymphoma due to a safety concern.
-
In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned.
-
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
-
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
-
Unum Captures Nearly $70 Million in IPO
3/29/2018
In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology. -
In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels.
-
Unum Therapeutics Expands Board with Appointment of Two Additional Directors
3/2/2018
Unum Therapeutics announced the appointment of Karen J. Ferrante, MD, and Robert J. Perez to its Board of Directors.
-
Unum Therapeutics Announces Appointment of Christiana Stamoulis to Additional Role of President
3/2/2018
Unum Therapeutics announced the appointment of Christiana Stamoulis to the additional role of President. Ms. Stamoulis has been Unum’s Chief Financial Officer and Head of Corporate Development since joining the Company in January 2015.
-
Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the Upcoming 59th ASH Annual Meeting
11/2/2017
The oral presentation will highlight early data from an ongoing Phase I dose escalation study, ATTCK-20-2 (ClinicalTrials.gov No. NCT02776813), of ACTR087 used in combination with rituximab in subjects with relapsed/refractory CD20+ B cell Non-Hodgkin lymphoma.
-
Unum Therapeutics to Present New Data on Its Antibody-Coupled T Cell Receptor (ACTR) Platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/30/2017
Unum Therapeutics announced that the Company will be presenting on its Antibody-Coupled T cell Receptor (ACTR) platform at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held in Philadelphia, PA on October 27-30, 2017.
-
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Combination With SEA-BCMA In Patients With Relapsed/Refractory Multiple Myeloma
8/23/2017
-
Unum Announces Active Investigational New Drug (IND) Application For ACTR707 In Combination With Rituximab In Patients With Relapsed/Refractory B-Cell Lymphoma
6/19/2017
-
Unum To Present Data On Its Antibody-Coupled T Cell Receptor (ACTR) Platform At The Upcoming Annual Meeting Of The American Society Of Gene & Cell Therapy (ASGCT)
5/9/2017
-
Unum To Present At 2016 Wedbush PacGrow Healthcare Conference
8/8/2016
-
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Patients With Relapsed/Refractory B-Cell Lymphoma
6/20/2016